Does BPC 157 Cause Cancer?

Your body already has a system for growing new blood vessels, and BPC-157 plugs directly into it. That's what makes it interesting for healing, and that's exactly what makes the cancer question worth taking seriously.

The system works like this. When tissue gets damaged, your body sends out chemical signals to build new blood vessels toward that damage so nutrients and repair cells can get in. The main signal in that process is something called VEGF, which stands for vascular endothelial growth factor, and it functions essentially as a construction order for new blood vessels. Cells that receive that order have surface proteins called VEGF receptors, and when VEGF binds to those receptors, the blood vessel building begins.

BPC-157 works by increasing the number of those receptors on the surface of your cells, specifically something called VEGFR2, which is the primary receptor that triggers the actual building response. More receptors means the same amount of VEGF signal produces a stronger construction response. A 2017 study testing this in rats with hind limb ischemia found that BPC-157 activated the VEGFR2-Akt-eNOS signaling pathway and measurably increased vessel density in damaged tissue. That is the mechanism behind the healing effect.

Now here is where the cancer concern enters the picture.

Tumors use the exact same construction order. When a solid tumor grows past a certain size, it cannot get enough oxygen and nutrients from nearby vessels, so it starts producing its own VEGF to hijack the construction system and build a dedicated blood supply toward itself. This process is called angiogenesis, which simply means the formation of new blood vessels, and without it a tumor cannot grow beyond a few millimeters. This is not a theoretical connection. Some of the most widely used cancer drugs, including bevacizumab, work specifically by blocking VEGF signaling to cut off that blood supply and starve the tumor. The fact that those drugs exist tells you how real and well-documented the VEGF-tumor relationship is.

So the concern with BPC-157 is a logical one. If the compound upregulates VEGFR2 and amplifies the sensitivity of cells to VEGF signals, and tumors rely on VEGF signals to build their blood supply, then in someone with an undetected or existing tumor, BPC-157 could theoretically accelerate that process.

That is the mechanism. Now here is what the actual evidence says.

There is one study that tested BPC-157 directly against cancer cells. It was a 2004 conference abstract that exposed SK-Mel-1 human melanoma cells to BPC-157 at concentrations of 2 nanograms and 10 nanograms, and found that cell division dropped by up to 55% compared to controls. That sounds like a protective finding, and it might be, but it is a single in vitro experiment on one cell line, produced by researchers in the same lab that has published most of the BPC-157 literature, and it has never been independently replicated in over 20 years. A result that cannot be reproduced is a hypothesis, not a conclusion.

More importantly, no study has ever tested BPC-157 in a living organism that has an actual tumor. No animal model with cancer. No measurement of tumor volume, tumor progression, or metastasis after BPC-157 exposure. A 2025 published commentary reviewing the available literature confirmed exactly this: there is no published in vivo data showing BPC-157 either promotes or inhibits tumor growth. The gap in the evidence is not a gap in one direction. It is a gap in both directions.

There is one additional mechanism worth naming. BPC-157 also activates something called FAK-paxillin signaling, which is a pathway associated with how cells attach to surfaces and move through tissue. This same pathway shows up in research on cancer cell invasion, meaning it is one of the mechanisms tumors use to spread. Whether BPC-157 activating this pathway in a cancer context is meaningful is unknown, but it is another biological thread that has not been investigated.

The practical read on all of this is straightforward. If you have no history of cancer, no active precancerous conditions, and no known elevated risk, the theoretical concern exists but there is no direct evidence that BPC-157 causes cancer in otherwise healthy people. The risk is unknown, not proven. Those are different things. If you have active cancer, a personal history of cancer, or a known precancerous condition, the combination of an upregulated angiogenic pathway and an uninvestigated FAK-paxillin effect gives you no margin of safety, and there is no data to suggest the risk is acceptable. Avoiding BPC-157 in that context is the only defensible position until better evidence exists.

Routine cancer screenings matter here more than most people realize. The scenario where BPC-157 would be most dangerous is one where a tumor is already present but undetected, and regular screening is the only tool that reduces that specific uncertainty.

The deeper point about BPC-157 is that its mechanism is not exotic or obscure. It works through the same biological pathways your body already uses to repair itself, and those pathways do not have labels that say "healing only." A signal that builds blood vessels toward an injury will also build blood vessels toward anything else that sends the same signal. The biology does not distinguish between the two. That is not a reason to dismiss the compound. It is a reason to understand what you are working with before you use it.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness